focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.55
Ask: 38.75
Change: -0.20 (-0.51%)
Spread: 0.20 (0.519%)
Open: 39.05
High: 39.20
Low: 39.00
Prev. Close: 39.20
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Manufacturing and Distribution Agreements with TTK

13 Jun 2016 07:00

RNS Number : 9244A
Futura Medical PLC
13 June 2016
 

For immediate release

13 June 2016

 

 

Futura Medical plc

("Futura" or the "Company")

 

Signs Manufacturing and Distribution Agreements with TTK

 

 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that it has signed manufacturing and distribution agreements with TTK Protective Devices Limited ("TTK"), a pioneer in the condom business and part of the substantial Indian conglomerate TTK Group.

 

Under the terms of the manufacturing agreement, TTK will manufacture CSD500, Futura's novel erectogenic condom for supply worldwide. A regulatory filing has already been made with EU regulatory authorities to grant TTK the relevant authorisation to manufacture the product.

 

TTK will be one of two manufacturers of CSD500 as part of the Company's strategy to guarantee international supply. A European manufacturer already holds regulatory authorisation to manufacture the version of CSD500 currently marketed in the Netherlands and is awaiting regulatory authorisation for the extended shelf-life version of the product.

 

Futura has also signed an exclusive licensing agreement with TTK for the marketing and distribution of CSD500 in India for the lifetime of the patents. Futura will receive an upfront payment and royalties on product sales over the duration of the agreement.

 

TTK already owns the fastest growing condom brand in India, SKORE, which since its launch three years ago has achieved in excess of a 10% market share. TTK is attracted by the unique characteristics of CSD500 to further drive the growth of the SKORE brand. Subject to regulatory approval, CSD500 is expected to be launched by TTK in Q1 2017.

 

James Barder, Futura Medical's Chief Executive, said: "I am delighted to sign these two agreements for worldwide manufacturing and for distribution in India of our novel erectogenic condom, CSD500. It has always been our manufacturing strategy to offer CSD500's licensees the guarantee of supply by having dual sourced manufacture in Europe and in Asia. TTK is an ideal manufacturing partner as it is a highly experienced condom maker that has supplied the world's largest condom brands.

 

"I am also delighted to sign an exclusive agreement with TTK for the marketing and distribution of CSD500 in India. TTK's SKORE brand is the fastest growing condom brand in India and we look forward to CSD500 becoming a further growth driver in the SKORE franchise."

 

Mr T T Raghunathan, TTK Protective Device's Managing Director, said: "We are very pleased to be working with Futura Medical both in manufacturing CSD500 for worldwide supply and in distributing the product in India. TTK has always stood for innovation and quality in the global condom market, in which we have a long track record in manufacturing high quality condoms. We also look forward to the success of combining India's fastest growing condom brand, SKORE, with the innovation that CSD500 brings to condom users."

 

 

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

Email to: james.barder@futuramedical.com

www.futuramedical.com

 

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Liz YongCorporate Finance

 

Tel:+44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan

Mark Court / Sophie Cowles / Stephanie Watson

Tel: +44 (0) 20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRGGURUQUPQGQU
Date   Source Headline
9th Jun 20213:58 pmRNSTR-1: Notification of major holdings
3rd Jun 20214:19 pmRNSTR-1: Notification of major holdings
3rd Jun 202111:00 amRNSNotice of AGM and Annual Report
2nd Jun 202112:50 pmRNSResult of General Meeting & Total Voting Rights
1st Jun 20217:00 amRNSBlock Listing Six Monthly Return
17th May 20213:08 pmRNSPosting of Circular and Notice of General Meeting
17th May 20217:00 amRNSResult of Placing and Retail Offer
14th May 20214:41 pmRNSSecond Price Monitoring Extn
14th May 20214:35 pmRNSPrice Monitoring Extension
14th May 20214:31 pmRNSRetail Offer by PrimaryBid
14th May 20214:30 pmRNSProposed Placing to raise £10 mil & Retail Offer
4th May 20215:18 pmRNSTR-1: Notification of major holdings
4th May 20215:15 pmRNSTR-1: Notification of major holdings
4th May 20217:00 amRNSTotal Voting Rights
30th Apr 20217:00 amRNSFutura Receives Approval from EU Notified Body
28th Apr 20212:57 pmRNSTR-1: Notification of major holdings
28th Apr 20219:31 amRNSTR-1: Notification of major holdings
22nd Apr 20214:58 pmRNSTR-1: Notification of major holdings
19th Apr 20214:03 pmRNSCorrection – Conversion of Convertible Loan Notes
15th Apr 20212:42 pmRNSConversion of Convertible Loan Notes
14th Apr 20213:40 pmRNSRemuneration of Non-Executive Directors and TVR
14th Apr 20217:00 amRNSFull Year Results for the year ended 31 Dec 2020
1st Apr 20214:20 pmRNSExercise of Warrants, Issue of Equity & TVR
30th Mar 20212:18 pmRNSNotice of Results
25th Mar 20214:41 pmRNSSecond Price Monitoring Extn
25th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 202111:05 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Mar 20212:05 pmRNSSecond Price Monitoring Extn
23rd Mar 20212:01 pmRNSPrice Monitoring Extension
23rd Mar 20219:05 amRNSSecond Price Monitoring Extn
23rd Mar 20219:00 amRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSUS FDA Agreement for Confirmatory Clinical study
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
19th Mar 202111:06 amRNSSecond Price Monitoring Extn
19th Mar 202111:00 amRNSPrice Monitoring Extension
19th Mar 20217:00 amRNSFutura Receives Recommendation for Approval
4th Mar 20212:05 pmRNSSecond Price Monitoring Extn
4th Mar 20212:00 pmRNSPrice Monitoring Extension
4th Mar 20219:06 amRNSSecond Price Monitoring Extn
4th Mar 20219:00 amRNSPrice Monitoring Extension
4th Mar 20217:00 amRNSFutura Announces Investment & Joint Collaboration
25th Feb 20212:06 pmRNSSecond Price Monitoring Extn
25th Feb 20212:01 pmRNSPrice Monitoring Extension
22nd Feb 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.